Internal Medicine Doctors in Ambridge, PA Accepting Medicare
3 Internal Medicine doctors found. Showing 1 - 3
 Dr. Hans J Fuchs, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1155 Merchant St, Ambridge, PA 15003 Phone: 724-266-0707 |
Dr. Richard A Schollaert, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1155 Merchant St, Ambridge, PA 15003 Phone: 724-266-0707 Fax: 724-266-3978 |
Dr. George B Cheponis, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1155 Merchant St, Ambridge, PA 15003 Phone: 724-266-0707 Fax: 724-266-3978 |
News Archive
Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved
A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine for its October 24, 2013 issue.
Artegraft BCA superior to cuffed ePTFE for hemodialysis access
Artegraft, Inc. announces that a three-year prospective, randomized clinical study published in the June 2011 issue of the Journal of Vascular Surgery confirms the superiority of Artegraft Bovine Carotid Artery vascular grafts (BCA) to cuffed ePTFE grafts.
Majority of Americans with diabetic foot ulcer suffer from PAD
A new analysis published by THE SAGE GROUP, concludes that peripheral artery disease (PAD) afflicts 2.0-3.7 million U.S. citizens with diabetic foot ulcers (DFU). Approximately 1 million diabetic foot ulcer patients suffer from the most severe and deadly form of PAD, critical limb ischemia.
FDA wants new warnings on antidepressant medications
The U.S. Food and Drug Administration (FDA) has proposed that makers of all antidepressant medications update the existing black box warning on their products' labeling to include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during initial treatment (generally the first one to two months).
› Verified 5 days ago